Javelin Pharmaceuticals, Inc. (NYSE Amex: JAV) announced today that its
CEO, Martin J. Driscoll, and Stephen J. Tulipano, CFO, will host a
conference call to discuss the Company's quarterly results for the
period ending September 30, 2009. The call will be held Tuesday,
November 10, 2009 at 8:30am EST.
The Company invites all interested parties to participate. The call will
be web cast live through the following URL: ir.javelinpharmaceuticals.com/events.cfm.
CONFERENCE CALL ALERT
Javelin Pharmaceuticals, Inc. Q3 2009 Earnings Call
Date: Tuesday, November 10, 2009
Time: 8:30am EST
Those interested in participating in the call should dial 877-874-1570
within the United States or 719-325-4774 internationally. The call will
be archived at the Company's website www.javelinpharmaceuticals.com.
About Javelin Pharmaceuticals, Inc.
With corporate headquarters in Cambridge, MA, Javelin applies innovative
proprietary technologies to develop new drugs and improved formulations
of existing drugs to target unmet and underserved medical needs in the
acute pain management market. The Company has one marketed drug in the
UK and three drug candidates in US Phase 3 clinical development. For
additional information about Javelin, please visit the Company's website
at http://www.javelinpharmaceuticals.com.
Forward Looking Statement:
This news release contains forward-looking statements. Such statements
are valid only as of today, and we disclaim any obligation to update
this information. These statements are subject to known and unknown
risks and uncertainties that may cause actual future experience and
results to differ materially from the statements made. These statements
are based on our current beliefs and expectations as to such future
outcomes. Drug discovery and development involve a high degree of risk.
Factors that might cause such a material difference include, among
others, uncertainties related to the ability to attract and retain
partners for our technologies, the identification of lead compounds, the
successful preclinical development thereof, the completion of clinical
trials, the FDA review process and other governmental regulation, our
ability to obtain working capital, our ability to successfully develop
and commercialize drug candidates, and competition from other
pharmaceutical companies.
JAV-E
(c) 2009 Business Wire, Inc., All rights reserved. All of the news releases and other content contained herein are protected by copyright and other applicable laws, treaties and conventions. Information contained in the releases is furnished by Business Wire's members, who warrant that they are solely responsible for the content, accuracy and originality of the information contained therein. Any copying or reproduction (other than for an individual user's personal reference), redistribution, reposting or other transmission or communication is expressly prohibited without prior written permission of Business Wire, Inc
